Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
- First Posted Date
- 2016-10-11
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 1134
- Registration Number
- NCT02929719
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
Phase 1
Completed
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 460
- Registration Number
- NCT02709902
Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
Phase 3
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: DSXSDrug: Placebo
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2018-12-10
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 119
- Registration Number
- NCT02618759
- Locations
- 🇺🇸
Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
Phase 2
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: DSXS
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 26
- Registration Number
- NCT02601469
- Locations
- 🇺🇸
Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis
Phase 2
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: DSXS
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT02595008
- Locations
- 🇺🇸
Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
Phase 3
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: DSXSDrug: Placebo
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 124
- Registration Number
- NCT02595073
- Locations
- 🇺🇸
Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States
A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris
Phase 1
Completed
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 1000
- Registration Number
- NCT02595034
A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris
Phase 1
Completed
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 844
- Registration Number
- NCT02578043
A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
Phase 2
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: DSXS1411Drug: Placebo
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 151
- Registration Number
- NCT02413229
Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris
Phase 1
Completed
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 753
- Registration Number
- NCT02411942
© Copyright 2025. All Rights Reserved by MedPath